H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Inclusion Criteria9

• Abilities to understand and the willingness to provide written informed consent;
• ≥ 2 and ≤ 70 years old;
• Recurrent or refractory diffuse midline glioma or diffuse intrinsic pontine glioma patients with confirmed H3K27M mutation and documented lesions. Patients have received standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ). Patients must either not be receiving dexamethasone or receiving ≤ 4 mg/day at the time of leukopheresis;
• Karnofsky performance score (KPS) ≥ 60;
• Life expectancy >3 months;
• Satisfactory bone marrow, liver and kidney functions as defined by the following: absolute neutrophile count ≥ 1500/mm\^3; hemoglobin > 10 g/dL; platelets > 100000 /mm\^3; Bilirubin < 1.5×ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5×ULN; creatinine < 1.5×ULN;
• Peripheral blood absolute lymphocyte count must be above 0.8×10\^9/L;
• Satisfactory heart functions;
• Must be willing to follow the instructions of doctors; Women of reproductive potential (between 15 and 49 years old) must have a negative pregnancy test within 7 days of study start. Male and female patients of reproductive potential must agree to use birth control during the study and 3 months post study.